search
Back to results

Low Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy (NIVO-LD)

Primary Purpose

HIV I Infection

Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
Nivolumab 10 MG/ML [Opdivo]
Nivolumab 10 MG/ML [Opdivo]
Saline
Sponsored by
University of Melbourne
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for HIV I Infection focused on measuring HIV, Antiretroviral interruption, ATI, Low dose Nivolumab, Clinical Trial

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Documented HIV-1 infection;
  • Viral load > 400 copies/mL prior to initiation of ART;
  • Weight ≥ 50 kg;
  • Ability and willingness to provide informed consent and to continue ART throughout the study;
  • Receiving combination ART for at least 2 years and being on the same ART regimen for at least 4 weeks at the screening visit;
  • HIV-1 plasma RNA <50 copies/mL for >2 years (documented on at least 2 occasions within the 2 years) and <50 copies/mL at screening. Episodes of a single HIV plasma RNA 50-500 copies/mL will not exclude participation if the subsequent HIV plasma RNA was <50 copies/mL;
  • CD4+ T cell counts >500 cells/μL at screening;
  • Female participants if they meet one of the following criteria:

    • Is of non-child-bearing potential defined as either post-menopausal (12 months of spontaneous amenorrhea and ≥ 45 years of age) or physically incapable of becoming pregnant with documented tubal ligation, hysterectomy or bilateral oophorectomy or,
    • Is of child-bearing potential with a negative pregnancy test at both Screening and Day 0 and agrees to use one of the following methods of contraception to avoid pregnancy from 14 days prior to the first infusion until the end of the study:

      • Complete abstinence from penile-vaginal intercourse;
      • Double barrier method (male condom/spermicide, male condom/diaphragm, diaphragm/spermicide);
      • Any intrauterine device (IUD) with published data showing that the expected failure rate is <1% per year;
      • Male partner sterilization confirmed prior to the female participant's entry into the study, and this male is the sole partner for that participant;
      • Approved hormonal contraception (Where other medications to be used in the study (e.g., efavirenz and darunavir) are known, or are likely, to significantly interact with systemic contraceptives, resulting in decreased efficacy of the contraceptive, then alternative methods of non-hormonal contraception are recommended);
      • Any other method with published data showing that the expected failure rate is <1% per year. Note: If using one of the described contraception methods it must be used consistently, in accordance with the approved product label and all female participants must be willing to undergo urine pregnancy tests as specified in the Schedule of Procedures.
  • All participants must agree not to participate in a conception process (e.g. active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization, egg donation) during the study;
  • Heterosexually active male if they are;

    • willing to use an effective method of contraception (anatomical sterility in self that is confirmed prior to study entry) or
    • agree on the use of an effective method of contraception with an effective failure rate of < 1% by his partner (hormonal contraception, intra-uterine device (IUD), or anatomical sterility) from the day of the first infusion until the end of study (as long as plasma viral load <20c/mL).

Exclusion Criteria:

  • Active, known and suspected autoimmune disease (including but not limited to including but not limited to inflammatory bowel diseases, scleroderma, severe psoriasis, myocarditis, uveitis, pneumonitis, systemic lupus erythematosus, rheumatoid arthritis, optic neuritis, myasthenia gravis, adrenal insufficiency, hypothyroidism and/or hyperthyroidism, autoimmune thyroiditis, sarcoidosis, and vitiligo);
  • History of interstitial lung disease;
  • History of chronic obstructive pulmonary disease (COPD);
  • Type I diabetes mellitus;
  • Active malignancy or history of malignancy requiring systemic chemotherapy or surgery in the preceding 24 months; exception -history of excised localized non-melanomatous skin cancers (squamous cell carcinoma, basal cell carcinoma);
  • History of solid organ transplant. Note Individuals with prior corneal transplants may be allowed to enrol after discussion with and approval from the study principal investigator;
  • Active or previously treated active TB;
  • History of HIV-related opportunistic infection within the last years prior to study entry;
  • Prior history of immune reconstitution syndrome (IRIS);
  • Current, chronic, acute or recurrent bacterial, fungal or viral (other than HIV) infections that are serious, in the opinion of the investigator, and require systemic therapy within 30 days prior to study entry;
  • Immune deficiency other than that caused by HIV infection;
  • Received investigational drug or device within 6 months prior to study entry
  • Treatment for hepatitis C virus (HCV) within 6 months prior to study entry;
  • History of previous treatment with an immune checkpoint inhibitor;
  • History of prior immunoglobulin (IgG) therapy;
  • Use of immunomodulators (e.g., interleukins, interferons, cyclosporine), systemic cytotoxic chemotherapy, experimental vaccines or investigational therapy within 60 days prior to study entry or intent to use immunomodulators during the study. NOTE: Participants receiving stable physiologic glucocorticoid doses, defined as prednisolone less than or equal to 10 mg/day or the equivalent, will not be excluded. Stable physiologic glucocorticoid doses should not be discontinued for the duration of the study. In addition, participants receiving inhaled or topical corticosteroids will not be excluded;
  • Any other current or prior therapy which, in the opinion of the investigators, would make the individual unsuitable for the study or influence the results of the study;
  • Participants with severe hepatic impairment (Class C) as determined by Child-Pugh classification;
  • Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice), known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones);
  • Patients who intend to modify their ART regimen within the study period;
  • Active alcohol or substance use that in the opinion of the investigator will prevent adequate compliance with study procedures;
  • Any acute or chronic psychiatric problems that, in the opinion of the investigator, make the participant ineligible for participation;
  • Any active, clinically significant medical condition not otherwise covered;
  • Women who are pregnant or breastfeeding or Women of Child Bearing Potential (WOCBP) who are unwilling or unable to use an acceptable method of contraception to avoid pregnancy as specified in the inclusion criteria;
  • Men of reproductive potential who are unwilling or unable to use an acceptable method of contraception to avoid pregnancy as specified in the inclusion criteria;
  • Specific exclusion criteria for Cohort A (Fine Needle Biopsy):

    • prothrombin time (PTT) >2x ULN
    • international normalized ratio (INR) >1.5
    • Platelets <50,000/mm3
    • Chronic venous stasis of lower extremities
    • Lower extremity lymphedema
    • Allergies to local anaesthetic
    • Blood coagulation disorder.
  • The following laboratory abnormalities (lab tests may be repeated to obtain acceptable values before failure at screening is concluded);

    • Haematology:

      • Haemoglobin < 14.0 g/dl for men and <12.0 g/dL for women;
      • Absolute Neutrophil Count (ANC) ≤ 1,500 /mm3 (≤ 1 x 10^9/l);
      • Platelets ≤ 150,000 /mm3
    • Biochemistry:

      • Aspartate aminotransferase (AST) > 1.25 x ULN;
      • Alanine aminotransferase (ALT) > 1.25 x ULN;
      • Bilirubin ≥1.5 x ULN (if on atazanavir ≥5 x ULN);
      • Interferon-gamma release assay (IGRA) for tuberculosis (TB) with negative results within 90 days prior to study entry
      • Thyroid stimulating hormone (TSH) outside the normal reference range;
      • Free thyroxine (T4) outside the normal reference range
      • Presence of Anti-thyroid peroxidase (TPO) antibodies;
      • Presence of anti-glutamic acid decarboxylase (GAD) antibodies
      • Antinuclear antibody (ANA) >1:80 at screening
      • Early morning (8-9 am) cortisol outside the normal reference range. Female participants on estrogen-containing oral contraception or other exogenous estrogen treatment may repeat the AM cortisol as part of screening to determine eligibility;
      • Fasting blood sugar within normal limits (unless already diagnosed with Type 2 Diabetes Mellitus);
    • Microbiology:

      • Positive for hepatitis B surface antigen;
      • Positive for hepatitis C antibody, unless confirmed clearance of HCV infection (spontaneous or following treatment) by polymerase chain reaction (PCR) testing.

Sites / Locations

  • Alfred Hospital - Department of Infecious DiseasesRecruiting
  • Tan Tock Seng Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

Dose escalation phase (Cohort A)

Randomization phase (Cohort B)

Randomization phase comparator (Cohort B)

Arm Description

Drug: Nivolumab Dose form: infusion Dose route: intravenous Dosage: 0.1, 0.3 or 1.0 mg/kg Duration: Single dose administered on Study Day 7

Drug: Nivolumab Dose form: infusion Dose route: intravenous Dosage: determined from Cohort 1 Duration: single dose administered on Day 0 (baseline)

Comparator: saline Dose form: infusion Dose route: intravenous Duration: single dose administered on Day 0 (baseline)

Outcomes

Primary Outcome Measures

Number of participants with treatment-emergent adverse events enrolled in Cohort A
Incidence and severity of Adverse Events (defined as Common Terminology Criteria (CTC) grade 3 or higher according to the Division of AIDS (DAIDS) grading table) that are definitely, probably or possibly related to study treatment during the study period
Number of participants with treatment-emergent adverse events enrolled in Cohort B
Incidence and severity of Adverse Events (defined as CTC grade 3 or higher according to the DAIDS grading table) that are definitely, probably or possibly related to study treatment during the study period

Secondary Outcome Measures

Change in PD-1 receptor occupancy in peripheral blood following a single low dose of nivolumab in participants enrolled in Cohort A
Time course change in the percentage PD-1 receptor occupancy on T-cells in peripheral blood determined by flow cytometry. Nivolumab infusion occurs on Day 7 study visit
Change in PD-1 receptor occupancy in lymph node T-cells following a single low dose of nivolumab in participants enrolled in Cohort A.
Time course change in the percentage PD-1 receptor occupancy on T-cells in inguinal lymph node T-cells determined by flow cytometry
Cohort A: T-cell responses to Gag peptides
Number of cluster of differentiation 4 (CD4) and/or cluster of differentiation 8 (CD8) T-cells responses to Gag peptides by intracellular cytokine staining both in peripheral blood and lymph nodes
Cohort A: T-cell responses to Pol/Env/Nef peptides
Number of CD4 and/or CD8 T-cells responses to Pol/Env/Nef peptides by intracellular cytokine staining in both peripheral blood and lymph nodes
Change in PD-1 receptor occupancy in peripheral blood following a single low dose of nivolumab in participants enrolled in Cohort B
Time course change in the percentage PD-1 receptor occupancy on T-cells in peripheral blood determined by flow cytometry. Nivolumab/placebo infusion occurs on Day 0 (baseline) visit
Cohort B: HIV RNA
Proportion of participants with a viral load (HIV RNA) > 50 and > 1000c/ml measured weekly during a 5-week ART interruption, which starts on Day 7 and ends on Day 35
Cohort B: viral rebound
Number of participants who experience a viral rebound (defined as first viral load > 50 copies/mL) during the 5 week ATI period which starts on Day 7 and ends on Day 35
Cohort B: T-cell responses to Gag peptides
Number of CD4 and/or CD8 T-cells responses to Gag peptides by intracellular cytokine staining both in peripheral blood and lymph nodes
Cohort B: T-cell responses to Pol/Env/Nef peptides
Number of CD4 and/or CD8 T-cells responses to Pol/Env/Nef peptides by intracellular cytokine staining in both peripheral blood and lymph nodes

Full Information

First Posted
December 15, 2021
Last Updated
February 5, 2023
Sponsor
University of Melbourne
Collaborators
The Alfred
search

1. Study Identification

Unique Protocol Identification Number
NCT05187429
Brief Title
Low Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy
Acronym
NIVO-LD
Official Title
Safety, Immunogenicity and Efficacy of Low Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy (ART)
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
January 24, 2023 (Actual)
Primary Completion Date
January 2024 (Anticipated)
Study Completion Date
January 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Melbourne
Collaborators
The Alfred

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to evaluate whether a single dose of Nivolumab in people living with HIV can reduce the latent reservoir. The latent HIV reservoir is a group of immune system cells in the body that are infected with HIV but are not actively producing new virus. This is the reason why people living with HIV are unable to stop their antiretroviral treatment.
Detailed Description
This study consists of 2 Parts. Part 1 is a dose escalation phase. This phase is open-label, single dose titration study in adult people living with HIV. There are 3 stages: a screening stage of up to 14 days; on study study treatment stage, where Nivolumab will be administered on Day 7 and a follow-up stage of 126 days (4 months). The maximum total duration on study for each participant enrolled in this phase is 140 days (4.5 months). Part 2 is a double-blind, randomized, placebo controlled clinical trial of a single fixed dose of Nivolumab administered intravenous (IV) infusion compared with placebo in adult people living with HIV. This part of the study will consist of 3 stages: a screening stage of up to 14 days; on study study treatment stage, where Nivolumab/placebo will be administered on Day 0, followed by a follow-up period which includes a 5-week pre-planned analytical treatment interruption (where antiretroviral therapy (ART) is ceased), before the participant re-commences ART. The maximum total duration on study for each participant enrolled in this phase is 200 days (approximately 6.5 months).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV I Infection
Keywords
HIV, Antiretroviral interruption, ATI, Low dose Nivolumab, Clinical Trial

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Sequential Assignment
Masking
ParticipantCare ProviderInvestigator
Masking Description
In Part 1 (Cohort A) - there is no masking and the Nivolumab administered is open-labeled. There is no randomization in this group. In Part 2 (Cohort B) - the participant, care provider and investigator are all masked to the treatment allocation. Participants in this group will be assigned to intervention treatment by chance.
Allocation
Randomized
Enrollment
42 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Dose escalation phase (Cohort A)
Arm Type
Experimental
Arm Description
Drug: Nivolumab Dose form: infusion Dose route: intravenous Dosage: 0.1, 0.3 or 1.0 mg/kg Duration: Single dose administered on Study Day 7
Arm Title
Randomization phase (Cohort B)
Arm Type
Experimental
Arm Description
Drug: Nivolumab Dose form: infusion Dose route: intravenous Dosage: determined from Cohort 1 Duration: single dose administered on Day 0 (baseline)
Arm Title
Randomization phase comparator (Cohort B)
Arm Type
Placebo Comparator
Arm Description
Comparator: saline Dose form: infusion Dose route: intravenous Duration: single dose administered on Day 0 (baseline)
Intervention Type
Drug
Intervention Name(s)
Nivolumab 10 MG/ML [Opdivo]
Intervention Description
Cohort A: Dose escalation phase: Nivolumab will be administered intravenously as a single dose in the dose escalation phase.
Intervention Type
Drug
Intervention Name(s)
Nivolumab 10 MG/ML [Opdivo]
Intervention Description
Cohort B: Randomisation phase: Nivolumab will be administered intravenously as a fixed single dose in the randomisation phase.
Intervention Type
Drug
Intervention Name(s)
Saline
Intervention Description
Cohort B: Randomisation phase: Saline will be administered intravenously as a single dose in the randomisation arm.
Primary Outcome Measure Information:
Title
Number of participants with treatment-emergent adverse events enrolled in Cohort A
Description
Incidence and severity of Adverse Events (defined as Common Terminology Criteria (CTC) grade 3 or higher according to the Division of AIDS (DAIDS) grading table) that are definitely, probably or possibly related to study treatment during the study period
Time Frame
18 weeks
Title
Number of participants with treatment-emergent adverse events enrolled in Cohort B
Description
Incidence and severity of Adverse Events (defined as CTC grade 3 or higher according to the DAIDS grading table) that are definitely, probably or possibly related to study treatment during the study period
Time Frame
24 weeks
Secondary Outcome Measure Information:
Title
Change in PD-1 receptor occupancy in peripheral blood following a single low dose of nivolumab in participants enrolled in Cohort A
Description
Time course change in the percentage PD-1 receptor occupancy on T-cells in peripheral blood determined by flow cytometry. Nivolumab infusion occurs on Day 7 study visit
Time Frame
Day 7, Day 14, Day 21, Day 35, Day 63, Day 91, Day 126
Title
Change in PD-1 receptor occupancy in lymph node T-cells following a single low dose of nivolumab in participants enrolled in Cohort A.
Description
Time course change in the percentage PD-1 receptor occupancy on T-cells in inguinal lymph node T-cells determined by flow cytometry
Time Frame
Day 21
Title
Cohort A: T-cell responses to Gag peptides
Description
Number of cluster of differentiation 4 (CD4) and/or cluster of differentiation 8 (CD8) T-cells responses to Gag peptides by intracellular cytokine staining both in peripheral blood and lymph nodes
Time Frame
Day 0, Day 126
Title
Cohort A: T-cell responses to Pol/Env/Nef peptides
Description
Number of CD4 and/or CD8 T-cells responses to Pol/Env/Nef peptides by intracellular cytokine staining in both peripheral blood and lymph nodes
Time Frame
Day 0, Day 126
Title
Change in PD-1 receptor occupancy in peripheral blood following a single low dose of nivolumab in participants enrolled in Cohort B
Description
Time course change in the percentage PD-1 receptor occupancy on T-cells in peripheral blood determined by flow cytometry. Nivolumab/placebo infusion occurs on Day 0 (baseline) visit
Time Frame
Day 0, Day 7, Day 28, Day 168
Title
Cohort B: HIV RNA
Description
Proportion of participants with a viral load (HIV RNA) > 50 and > 1000c/ml measured weekly during a 5-week ART interruption, which starts on Day 7 and ends on Day 35
Time Frame
5 weeks
Title
Cohort B: viral rebound
Description
Number of participants who experience a viral rebound (defined as first viral load > 50 copies/mL) during the 5 week ATI period which starts on Day 7 and ends on Day 35
Time Frame
5 weeks
Title
Cohort B: T-cell responses to Gag peptides
Description
Number of CD4 and/or CD8 T-cells responses to Gag peptides by intracellular cytokine staining both in peripheral blood and lymph nodes
Time Frame
Day 7, Day 168
Title
Cohort B: T-cell responses to Pol/Env/Nef peptides
Description
Number of CD4 and/or CD8 T-cells responses to Pol/Env/Nef peptides by intracellular cytokine staining in both peripheral blood and lymph nodes
Time Frame
Day 7, Day 168

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Documented HIV-1 infection; Viral load > 400 copies/mL prior to initiation of ART; Weight ≥ 50 kg; Ability and willingness to provide informed consent and to continue ART throughout the study; Receiving combination ART for at least 2 years and being on the same ART regimen for at least 4 weeks at the screening visit; HIV-1 plasma RNA <50 copies/mL for >2 years (documented on at least 2 occasions within the 2 years) and <50 copies/mL at screening. Episodes of a single HIV plasma RNA 50-500 copies/mL will not exclude participation if the subsequent HIV plasma RNA was <50 copies/mL; CD4+ T cell counts >500 cells/μL at screening; Female participants if they meet one of the following criteria: Is of non-child-bearing potential defined as either post-menopausal (12 months of spontaneous amenorrhea and ≥ 45 years of age) or physically incapable of becoming pregnant with documented tubal ligation, hysterectomy or bilateral oophorectomy or, Is of child-bearing potential with a negative pregnancy test at both Screening and Day 0 and agrees to use one of the following methods of contraception to avoid pregnancy from 14 days prior to the first infusion until the end of the study: Complete abstinence from penile-vaginal intercourse; Double barrier method (male condom/spermicide, male condom/diaphragm, diaphragm/spermicide); Any intrauterine device (IUD) with published data showing that the expected failure rate is <1% per year; Male partner sterilization confirmed prior to the female participant's entry into the study, and this male is the sole partner for that participant; Approved hormonal contraception (Where other medications to be used in the study (e.g., efavirenz and darunavir) are known, or are likely, to significantly interact with systemic contraceptives, resulting in decreased efficacy of the contraceptive, then alternative methods of non-hormonal contraception are recommended); Any other method with published data showing that the expected failure rate is <1% per year. Note: If using one of the described contraception methods it must be used consistently, in accordance with the approved product label and all female participants must be willing to undergo urine pregnancy tests as specified in the Schedule of Procedures. All participants must agree not to participate in a conception process (e.g. active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization, egg donation) during the study; Heterosexually active male if they are; willing to use an effective method of contraception (anatomical sterility in self that is confirmed prior to study entry) or agree on the use of an effective method of contraception with an effective failure rate of < 1% by his partner (hormonal contraception, intra-uterine device (IUD), or anatomical sterility) from the day of the first infusion until the end of study (as long as plasma viral load <20c/mL). Exclusion Criteria: Active, known and suspected autoimmune disease (including but not limited to including but not limited to inflammatory bowel diseases, scleroderma, severe psoriasis, myocarditis, uveitis, pneumonitis, systemic lupus erythematosus, rheumatoid arthritis, optic neuritis, myasthenia gravis, adrenal insufficiency, hypothyroidism and/or hyperthyroidism, autoimmune thyroiditis, sarcoidosis, and vitiligo); History of interstitial lung disease; History of chronic obstructive pulmonary disease (COPD); Type I diabetes mellitus; Active malignancy or history of malignancy requiring systemic chemotherapy or surgery in the preceding 24 months; exception -history of excised localized non-melanomatous skin cancers (squamous cell carcinoma, basal cell carcinoma); History of solid organ transplant. Note Individuals with prior corneal transplants may be allowed to enrol after discussion with and approval from the study principal investigator; Active or previously treated active TB; History of HIV-related opportunistic infection within the last years prior to study entry; Prior history of immune reconstitution syndrome (IRIS); Current, chronic, acute or recurrent bacterial, fungal or viral (other than HIV) infections that are serious, in the opinion of the investigator, and require systemic therapy within 30 days prior to study entry; Immune deficiency other than that caused by HIV infection; Received investigational drug or device within 6 months prior to study entry Treatment for hepatitis C virus (HCV) within 6 months prior to study entry; History of previous treatment with an immune checkpoint inhibitor; History of prior immunoglobulin (IgG) therapy; Use of immunomodulators (e.g., interleukins, interferons, cyclosporine), systemic cytotoxic chemotherapy, experimental vaccines or investigational therapy within 60 days prior to study entry or intent to use immunomodulators during the study. NOTE: Participants receiving stable physiologic glucocorticoid doses, defined as prednisolone less than or equal to 10 mg/day or the equivalent, will not be excluded. Stable physiologic glucocorticoid doses should not be discontinued for the duration of the study. In addition, participants receiving inhaled or topical corticosteroids will not be excluded; Any other current or prior therapy which, in the opinion of the investigators, would make the individual unsuitable for the study or influence the results of the study; Participants with severe hepatic impairment (Class C) as determined by Child-Pugh classification; Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice), known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones); Patients who intend to modify their ART regimen within the study period; Active alcohol or substance use that in the opinion of the investigator will prevent adequate compliance with study procedures; Any acute or chronic psychiatric problems that, in the opinion of the investigator, make the participant ineligible for participation; Any active, clinically significant medical condition not otherwise covered; Women who are pregnant or breastfeeding or Women of Child Bearing Potential (WOCBP) who are unwilling or unable to use an acceptable method of contraception to avoid pregnancy as specified in the inclusion criteria; Men of reproductive potential who are unwilling or unable to use an acceptable method of contraception to avoid pregnancy as specified in the inclusion criteria; Specific exclusion criteria for Cohort A (Fine Needle Biopsy): prothrombin time (PTT) >2x ULN international normalized ratio (INR) >1.5 Platelets <50,000/mm3 Chronic venous stasis of lower extremities Lower extremity lymphedema Allergies to local anaesthetic Blood coagulation disorder. The following laboratory abnormalities (lab tests may be repeated to obtain acceptable values before failure at screening is concluded); Haematology: Haemoglobin < 14.0 g/dl for men and <12.0 g/dL for women; Absolute Neutrophil Count (ANC) ≤ 1,500 /mm3 (≤ 1 x 10^9/l); Platelets ≤ 150,000 /mm3 Biochemistry: Aspartate aminotransferase (AST) > 1.25 x ULN; Alanine aminotransferase (ALT) > 1.25 x ULN; Bilirubin ≥1.5 x ULN (if on atazanavir ≥5 x ULN); Interferon-gamma release assay (IGRA) for tuberculosis (TB) with negative results within 90 days prior to study entry Thyroid stimulating hormone (TSH) outside the normal reference range; Free thyroxine (T4) outside the normal reference range Presence of Anti-thyroid peroxidase (TPO) antibodies; Presence of anti-glutamic acid decarboxylase (GAD) antibodies Antinuclear antibody (ANA) >1:80 at screening Early morning (8-9 am) cortisol outside the normal reference range. Female participants on estrogen-containing oral contraception or other exogenous estrogen treatment may repeat the AM cortisol as part of screening to determine eligibility; Fasting blood sugar within normal limits (unless already diagnosed with Type 2 Diabetes Mellitus); Microbiology: Positive for hepatitis B surface antigen; Positive for hepatitis C antibody, unless confirmed clearance of HCV infection (spontaneous or following treatment) by polymerase chain reaction (PCR) testing.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Barbara Scher
Phone
+61 (0)3 8344 0770
Email
barbara.scher@unimelb.edu.au
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sharon Lewin
Organizational Affiliation
University of Melbourne
Official's Role
Principal Investigator
Facility Information:
Facility Name
Alfred Hospital - Department of Infecious Diseases
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3181
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Clinical Research Coordinator
Phone
+61 (0)3 9076 6908
Email
clinresearch@alfred.org.au
Facility Name
Tan Tock Seng Hospital
City
Singapore
ZIP/Postal Code
308433
Country
Singapore
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chen Seong Wong
Phone
+65 9726 0256
Email
mailto:Chen_Seong_Wong@ncid.sg
First Name & Middle Initial & Last Name & Degree
Travis Chia
Phone
+65 6511 5034
Email
mailto:Travis_RT_CHIA@ncid.sg
First Name & Middle Initial & Last Name & Degree
Chen Seong Wong

12. IPD Sharing Statement

Learn more about this trial

Low Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy

We'll reach out to this number within 24 hrs